Body iron stores and the risk of carotid atherosclerosis: Prospective results from the bruneck study

Circulation

Volumn 96, Issue 10, 1997, Pages 3300-3307

  Kiechl, Stefan ^a   Willeit, Johann ^b   Egger, Georg ^b   Poewe, Werner ^b   Oberhollenzer, Friedrich ^b  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b NONE

Author keywords

Atherosclerosis; Follow up studies; Lipoproteins; Myocardial infarction; Population

Indexed keywords

FERRITIN; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CAROTID ARTERY; ECHOGRAPHY; FEMALE; FERRITIN BLOOD LEVEL; HEART INFARCTION; HUMAN; IRON OVERLOAD; IRON STORAGE; LIPID PEROXIDATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; VASCULAR DISEASE;

EID: 0030778795     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.10.3300     Document Type: Article

References (72)

1. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet. 1981;1:1293-1294.
2. Sullivan JL. The iron paradigm of ischemic heart disease. Am Heart J. 1989;117:1177-1188.
3. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modification of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
4. Maggi E, Chiesa R, Melissano G, Castellano R, Astore D, Grossi A, Finardi G, Bellomo G. LDL oxidation in patients with severe carotid atherosclerosis: a study of in vitro and in vivo oxidation markers. Arterioscler Thromb. 1994;14:1892-1899.
5. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A. 1987;84:2995-2998.
6. Haber F, Weiss J. The catalytic decomposition of hydrogen peroxide by iron salts. Proc R Soc Ser A. 1934;147:332-351.
7. Kiechl S, Aichner F, Gerstenbrand F, Egger G, Mair A, Rungger G, Spögler F, Jarosch E, Oberhollenzer F, Willeit J. Body iron stores and presence of carotid atherosclerosis: results from the Bruneck Study. Arterioscler Thromb. 1994;14:1625-1630.
8. Willeit J, Kiechl S. Prevalence and risk factors of asymptomatic extracranial carotid artery atherosclerosis: a population-based study. Arterioscler Thromb. 1993;13:661-668.
9. Ricotta JJ, Bryan FA, Bond MG, Kurtz A, O'Leary DH, Toole JF. Multicenter validation of real-time (B-mode) ultrasound, arteriography, and pathologic examination. Surgery. 1987;6:512-520.
10. Crouse JR, Harpold GH, Kahl FR, Toole JF, McKinney WM. Evaluation of a scoring system for extracranial carotid atherosclerosis extent with B-mode ultrasound. Stroke. 1986;17:270-275.
11. Kiechl S, Willeit J, Egger G, Oberhollenzer M, Aichner F. Alcohol consumption and carotid atherosclerosis: evidence of dose-dependent atherogenic and antiatherogenic effects: results from the Bruneck Study. Stroke. 1994;25:1593-1598.
12. IHD Register: Report of the Fifth Working Group. Copenhagen, Denmark: World Health Organization, Regional Office for Europe; 1971.
13. Walker A, Robins M, Weinfeld F. The National Survey of Stroke: clinical findings. Stroke. 1981;12(suppl I):I-13-I-49.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
15. Kiechl S, Willeit J, Poewe W, Egger G, Oberhollenzer F, Muggeo M, Bonora E. Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study). BMJ. 1996;313:1040-1044.
16. Breslow NE, Day NE. Statistical Methods in Cancer Research, Vol 2: The Design and Analysis of Cohort Studies. New York, NY: Oxford University Press; 1987.
17. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons; 1988.
18. Wilcosky TC, Chambless LE. A comparison of direct adjustment and regression adjustment of epidemiologic measures. J Chronic Dis. 1985;38:849-856.
19. Flanders WD, Rhodes PH. Large sample confidence intervals for regression standardized risks, risk ratios, and risk differences. J Chronic Dis. 1987;40:697-704.
20. Cox DR, Oakes D. Analysis of Survival Data. London, UK: Chapman & Hall; 1984.
21. Salonen R, Nyyssönen K, Porkkala-Sarataho E, Salonen JT. The Kuopio atherosclerosis prevention study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol. 1995;76:34C-39C.
22. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer. 1994;69:979-985.
23. Fuhrman B, Oiknine J, Aviram M. Iron induces lipid peroxidation in cultured macrophages, increases their ability to oxidatively modify LDL, and affects their secretory properties. Atherosclerosis. 1994;111:65-78.
24. Heinecke JW, Rosen H, Chait A. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest. 1984;74:1890-1894.
25. Evans PJ, Smith C, Mitchinson MJ, Halliwell B. Metal ion release from mechanically-disrupted human arterial wall. Free Radic Res. 1995;23:465-469.
26. Balla G, Jacob HS, Eaton JW, Belcher JD, Vercellotti GM. Hemin: a possible physiological mediator of low density lipoprotein oxidation and endothelial injury. Arterioscler Thromb. 1991;11: 1700-1711.
27. Yuan XM, Brunk UT, Olsson AG. Effects of iron- and hemoglobin-loaded human monocyte-derived macrophages on oxidation and uptake of LDL. Arterioscler Thromb Vasc Biol. 1995;15:1345-1351.
28. Lapenna D, De Gioia S, Mezzetti A, Ciofani G, Consoli A, Marzio L, Cuccurullo F. Cigarette smoke, ferritin, and lipid peroxidation. Am J Respir Crit Care Med. 1995;151:431-435.
29. Reif DW. Ferritin as a source of iron for oxidative damage. Free Radic Biol Med. 1992;2:417-427.
30. Thomas CE, Morehouse LA, Aust SA. Ferritin and superoxide-dependent lipid peroxidation. J Biol Chem. 1985;260:3275-3280.
31. Abdalla DSP, Campa A, Monteiro HP. Low density lipoprotein oxidation by stimulated neutrophils and ferritin. Atherosclerosis. 1992;97:149-159.
32. Biemond P, Swaak AJ, Beindorff CM, Koster JF. Superoxide-dependent and -independent mechanisms of iron mobilization from ferritin by xanthine oxidase: implications for oxygen-free-radical-induced tissue destruction during ischaemia and inflammation. Biochem J. 1986;239:169-173.
33. Crawford DW, Blankenhorn DH. Arterial wall oxygenation, oxyradicals, and atherosclerosis. Atherosclerosis. 1991;89:97-108.
34. Swain J, Gutteridge JM. Prooxidant iron and copper, with ferroxidase and xanthine oxidase activities in human atherosclerotic material. FEBS Lett. 1995;368:513-515.
35. Smith C, Mitchinson MJ, Aruoma OI, Halliwell B. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J. 1992;286:901-905.
36. Craig WY, Poulin SE, Palomaki GE, Neveux LM, Ritchie RF, Ledue TB. Oxidation-related analytes and lipid and lipoprotein concentrations in healthy subjects. Arterioscler Thromb Vasc Biol. 1995;15:733-739.
37. Murray MJ, Murray AB, Murray NJ. Do iron and copper supplementation of the diet impair antioxidant activity and speed atherogenesis? Arterioscler Thromb. 1991;11:1479a. Abstract.
38. Salonen JT, Korpela H, Nyyssönen K, Porkkala E, Tuomainen TP, Belcher JD, Jacobs DR, Salonen R. Lowering of body iron stores by blood letting and oxidation resistance of serum lipoproteins: a randomized cross-over trial in male smokers. J Intern Med. 1995; 237:161-168.
39. Araujo JA, Romano EL, Brito BE, Parthé V, Romano M, Bracho M, Montaño RF, Cardier J. Iron overload augments the development of atherosclerotic lesions in rabbits. Arterioscler Thromb Vasc Biol. 1995;15:1172-1180.
40. Harats D, Ben-Naim M, Dabach Y, Hollander G, Stein O, Stein Y. Cigarette smoking renders LDL susceptible to peroxidative modification and enhanced metabolism by macrophages. Atherosclerosis. 1989;79:245-252.
41. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-250.
42. Porreca E, Ucchino S, Di Febbo C, Di Bartolomeo N, Angelucci D, Napolitano AM, Mezzetti A, Cuccurullo F. Antiproliferative effect of deferrioxamine on vascular smooth muscle cells in vitro and in vivo. Arterioscler Thromb. 1994;14:299-304.
43. Cazzola M, Bergamaschi G, Dezza L, Arosio P. Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood. 1990;75: 1903-1919.
44. Cook JD, Lipschitz DA, Miles LE, Finch CA. Serum ferritin as a measure of iron stores in normal subjects. Am J Clin Nutr. 1974;27: 681-687.
45. Lipschitz DA, Cook JD, Finch CA. A clinical evaluation of serum ferritin as an index of iron stores. N Engl J Med. 1974;290. 1213-1216.
46. Finch CA, Huebers H. Perspectives in iron metabolism. N Engl J Med. 1982;306:1520-1528.
47. Weinberg ED. Iron withholding: a defense against infection and neoplasia. Physiol Rev. 1984;64:64-102.
48. Hercberg S, Galan P, Dhur A. Essential mineral and trace element nutriture methodology: iron. In: Fidanza F, ed. Nutritional Status Assessment. London, UK: Chapman & Hall; 1991:355-384.
49. Xu Q, Willeit J, Marosi M, Kleindienst R, Oberhollenzer F, Kiechl S, Stulnig T, Luef G, Wick G. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet. 1993; 341:255-259.
50. Weiss G, Willeit J, Kiechl S, Fuchs D, Jarosch E, Oberhollenzer F, Reibnegger G, Tilz GP, Gerstenbrand F, Wachter H. Increased concentrations of interferon-gamma inducible factor neopterin in carotid atherosclerosis. Atherosclerosis. 1994;106:263-271.
51. Rauramaa R, Vaisanen S, Mercuri M, Litmanen H, Väisänen SB, Julkunen A, Penttilä IM, Bond MG. Association of risk factors and body iron status to carotid atherosclerosis in middle-aged eastern Finnish men. Eur Heart J. 1994;15:1020-1027.
52. Moore M, Folsom AR, Barnes RW, Eckfeldt JH. No association between serum ferritin and asymptomatic carotid atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol. 1995;141:719-723.
53. Sullivan JL. Iron, asymptomatic carotid atherosclerosis, and myocardial infarction. Am J Epidemiol. 1995;141:719-723.
54. Gillum RF, Sempos CT, Makuc DM, Looker AC, Chien CY, Ingram DD. Serum transferrin saturation, stroke incidence, and mortality in women and men: the NHANES I Epidemiologic Followup Study. Am J Epidemiol. 1996;144:59-68.
55. Takkunen H, Reunanen A, Knekt P, Aromaa A. Body iron stores and the risk of cancer. N Engl J Med. 1989;320:1013-1014.
56. Baer DM, Tekawa IS, Hurley LB. Iron stores are not associated with acute myocardial infarction. Circulation. 1994;89:2915-2918.
57. Magnusson MK, Sigfusson N, Sigvaldason H, Johannesson GM, Magnusson S, Thorgeirsson G. Low iron-binding capacity as a risk factor for myocardial infarction. Circulation. 1994;89:102-108.
58. Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992;86: 803-811.
59. Mänttäri M, Manninen V, Huttunen JK, Palosuo T, Ehnholm C, Heinonen OP, Frick MH. Serum ferritin and ceruloplasmin as coronary risk factors: a nested case-control study in the Helsinki Heart Study Population. Circulation. 1993;88(suppl I):I-70. Abstract.
60. Salonen JT, Nyyssönen K, Salonen R. Body iron stores and the risk of coronary heart disease. N Engl J Med. 1994;31:1159. Abstract.
61. Ascherio A, Willett WC, Rimm EB, Giovannucci EL, Stampfer MJ. Dietary iron intake and risk of coronary disease among men. Circulation. 1994;89:969-974.
62. Aronow WS. Serum ferritin is not a risk factor for coronary artery disease in men and women aged ≥62 years. Am J Cardiol. 1993;72: 347-348.
63. Stampfer MJ, Grodstein F, Rosenberg I, Willett WC, Hennekens C. A prospective study of plasma ferritin and risk of myocardial infarction in US physicians. Circulation. 1993;87:688. Abstract.
64. Sempos CT, Looker AC, Gillum RF, Makuc DM. Body iron stores and the risk of coronary heart disease. N Engl J Med. 1994;330: 1119-1124.
65. Lauffer RB. Iron stores and the international variation in mortality from coronary artery disease. Med Hypotheses. 1991;35:96-102.
66. Liao Y, Cooper RS, McGee DL. Iron status and coronary heart disease: negative findings from the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol. 1994;139:704-712.
67. Morrison HI, Semenciw RM, Mao Y, Wigle DT. Serum iron and risk of fatal acute myocardial infarction. Epidemiology. 1994;5: 243-246.
68. Ascherio A, Willett WC. Are body iron stores related to the risk of coronary heart disease? N Engl J Med. 1994;330:1152-1154.
69. Regnström J, Tornvall P, Kallner A, Nilsson J, Hamsten A. Stored iron levels and myocardial infarction at young age. Atherosclerosis. 1994;106:123-125.
70. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and the risk of cardiovascular disease: the Framingham Study. Ann Intern Med. 1976;85:447-452.
71. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation. 1974;49:476-488.
72. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756-762.